Himax Collaborates With Wentai Over Smart Workspace Solution

Himax Technologies, Inc (NASDAQ:HIMX) collaborates with Wentai Technology to exhibit a smart office solution enabled by Himax WiseEye smart image…
  • Himax Technologies, Inc (NASDAQ:HIMX) collaborates with Wentai Technology to exhibit a smart office solution enabled by Himax WiseEye smart image sensing solution at CES 2023 in Las Vegas, Nevada.
  • The smart office solution incorporates Himax WiseEye’s total solution, including ultralow power WE1 AI processor, HM0360 always-on CMOS image sensor, and proprietary occupancy management AI algorithm. 
  • The occupancy management AI conducts people presence detection, people counting and location in an office with ultralow power consumption, transmitting only byte-sized metadata output to larger back-end systems or cloud servers for further statistical analysis. 
  • Also Read: Himax Registers 31.7% Sequential Revenue Decline In Q3
  • The smart office solution can operate in a low-bandwidth network environment with reduced energy consumption while providing increased security and privacy protection.
  • “Himax’s WiseEye total solution featuring ultralow power and easy-to-design characteristics, coupled with our leading lighting and office management technology, provides a smart office solution that can work in a low bandwidth environment,” said Steven Wang, VP, Sales & Technical Chief at Wentai.
  • At CES, Himax and Wentai will provide a live showcase of the smart office solution. 
  • Price Action: HIMX shares closed lower by 4.76% at $6.40 on Tuesday.
  • Photo Via Company
Total
0
Shares
Related Posts
Read More

Abbott Labs Announced New Five-year Data Presented At American College Of Cardiology Scientific Sessions And Simultaneously Published In The New England Journal Of Medicine Reinforce The Long-term Safety And Effectiveness Of Mitraclip For Treating Seco…

Abbott (NYSE: ABT) today announced late-breaking data for MitraClip™, the leading therapy to treat leaky valves in people with mitral regurgitation (MR), that demonstrate long-term benefits of the device in patients battling heart failure.

ABT